Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer

Bookmark and Share
Published: 29 May 2020
Views: 864
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Dr Julie Gralow speaks to ecancer online about her ASCO 2020 virtual presentation which discussed the SWOG S1416 trial.

SWOG S1416 was a phase II randomised trial of cisplatin /- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer.

She explains the reason for choosing veliparib for this study, and the general trial design.

Dr Gralow explains the results, good for the BRCA patients, before touching upon the side effects.